Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 8/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18430031 | 1.00 | EIF2AK4 (0.36) | EIF2AK4BRS3PIM2RETPIM1 | |
| SCHEMBL15873372 | 0.92 | PIM2 (0.37) | EIF2AK4BRS3PIM2RETPIM1 | |
| SCHEMBL16587791 | 0.90 | PIM2 (0.38) | PIM2PIM1PIM3 | |
| SCHEMBL15883556 | 0.90 | PIM2 (0.35) | EIF2AK4BRS3PIM2PIM1PIM3 | |
| SCHEMBL18949917 | 0.89 | EIF2AK4 (0.35) | EIF2AK4BRS3PIM2RETPIM1 | |
| SCHEMBL15547790 | 0.89 | EIF2AK4 (0.34) | EIF2AK4BRS3PIM2RETPIM1 | |
| SCHEMBL15883550 | 0.88 | PIM2 (0.39) | EIF2AK4BRS3PIM2PIM1PIM3 | |
| SCHEMBL16588191 | 0.86 | EIF2AK4 (0.39) | EIF2AK4BRS3PIM2PIM1PIM3 | |
| SCHEMBL18430046 | 0.86 | BRS3 (0.35) | EIF2AK4BRS3 | |
| SCHEMBL19371100 | 0.86 | BRS3 (0.35) | EIF2AK4BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9676750-B2 | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-9556197-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160137626-A1 | BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2016-05-19 | — | — | US | disclosed |
| US-9278950-B2 | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2935270-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | Novartis AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2861585-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140200216-A1 | BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2014110574-A1 | BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014099880-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014099880-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013175388-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013175388-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | EIF2AK4 710/4885BRS3 3853/4885PIM2 2/4885 |
| US-20160137626-A1 | BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | EIF2AK4 258/4885BRS3 3074/4885PIM2 2/4885 |
| US-20140200216-A1 | BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | EIF2AK4 258/4885BRS3 3074/4885PIM2 2/4885 |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | EIF2AK4 710/4885BRS3 3853/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.